TABLE: In turbulent week, 2 IPOs price, 6 test waters
This article was originally published in Scrip
Executive Summary
While the biotechnology industry continues to debate whether the window for initial public offerings is closing, two drug developers priced IPOs during a US stock trading week shortened by the July 4th holiday and six revealed their plans to become public companies.
You may also be interested in...
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.